» Articles » PMID: 2790622

Epidemiologic Features of Hepatitis B Virus Infection in Northern Labrador

Overview
Journal CMAJ
Date 1989 Oct 15
PMID 2790622
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the epidemiologic features of hepatitis B virus (HBV) infection in northern Labrador to determine the prevalence of the infection and to obtain a database to develop a vaccination strategy. The study population included seven communities in which five ethnic groups were represented: Inuit, Innu, mixed Inuit and European ancestry ("settler"), nonnative/nonsettler transient population ("white") and people of Innu-white or Innu-Inuit origin ("mixed"). Blood samples from 2156 people (62% of the area residents) were tested for antibody to HBV core antigen (anti-HBc), HBV surface antigen (HBsAg), HBV e antigen (HBeAg), anti-HBc IgM and antibody to the surface antigen (anti-HBs). The overall crude prevalence rate of HBV seromarkers was 14.7% and the HBsAg carrier rate at least 3.2%; the rates were highest for Inuit (26.4% and 6.9% respectively), followed by settler (10.0% and 1.9% respectively) and Innu (7.6% and 0.4% respectively); the white and mixed groups had the lowest overall rates (2.5% and 3.3% respectively). Although the overall prevalence rates were about the same for the two sexes, the HBsAg carrier rate was higher in males (male:female ratio 1.6:1.0). No HBV carriers were positive for HBeAg or anti-HBc IgM antibody. The rate of exposure to HBV was 4% for those below the age of 20 years and reached a peak for those aged 45 to 54 years (85% for Inuit, 40% for settlers and 37% for Innu). There was also a wide variation in the age-standardized prevalence rates (0% to 27.9%) among the ethnic groups in the seven communities surveyed.

Citing Articles

Hepatitis B among Inuit: A review with focus on Greenland Inuit.

Rex K, Andersen S, Krarup H World J Hepatol. 2015; 7(9):1265-71.

PMID: 26019742 PMC: 4438501. DOI: 10.4254/wjh.v7.i9.1265.


Chronic hepatitis B infection in Canada.

Minuk G, Uhanova J Can J Infect Dis. 2007; 12(6):351-6.

PMID: 18159362 PMC: 2094840. DOI: 10.1155/2001/650313.


Epidemiology of hepatitis B in Canada.

Zhang J, Zou S, Giulivi A Can J Infect Dis. 2007; 12(6):345-50.

PMID: 18159361 PMC: 2094839. DOI: 10.1155/2001/790915.


Epidemiological study of hepatitis B virus infection in Manitoba, Canada, 1992-2003.

Hong Z, Smart G, Zaniewski G, Wu H, Wu J, Goedhuis N Eur J Clin Microbiol Infect Dis. 2005; 24(7):464-70.

PMID: 15959814 DOI: 10.1007/s10096-005-1350-6.

References
1.
Blumberg B, Gerstley B, HUNGERFORD D, London W, Sutnick A . A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med. 1967; 66(5):924-31. DOI: 10.7326/0003-4819-66-5-924. View

2.
Sutnick A, London W, Gerstley B, Cronlund M, Blumberg B . Anicteric hepatitis associated with Australia antigen. Occurrence in patients with Down's syndrome. JAMA. 1968; 205(10):670-4. View

3.
DUDLEY F, Scheuer P, Sherlock S . Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet. 1972; 2(7792):1388-93. DOI: 10.1016/s0140-6736(72)92963-7. View

4.
Barrett D, Burks J, McMahon B, Elliott S, Berquist K, Bender T . Epidemiology of hepatitis B in two Alaska communities. Am J Epidemiol. 1977; 105(2):118-22. DOI: 10.1093/oxfordjournals.aje.a112362. View

5.
Skinhoj P . Hepatitis and hepatitis B-antigen in Greenland. II: Occurrence and interrelation of hepatitis B associated surface, core, and "e" antigen-antibody systems in a highly endemic area. Am J Epidemiol. 1977; 105(2):99-106. DOI: 10.1093/oxfordjournals.aje.a112371. View